References
- Centers for Disease Control. Reported tuberculosis in the United States. US Department of Health and Human Services, Atlanta GA. September 2004
- Centers for Disease Control. Prevention and control of tuberculosis in facilities providing long-term care to the elderly. MMWR Morb Mortal Wkly Rep 1990;39:7–20
- Centers for Disease Control. A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1989;38(Suppl S-3):1–25
- American Thoracic Society. Preventive therapy of tuberculosis infection. Am Rev Respir Dis 1974;110:371–3
- Taylor WC, Aronson MD, Delbanco TL. Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med 1981;94:808–13
- Mehta JB, Dutt AK, Harvill L, et al. Isoniazid preventive therapy for tuberculosis: are we losing our enthusiasm? Chest1988:94;138–41
- American Thoracic Society. Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis 1983;127:790–6
- Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a seven year survey from a public health clinic. J Am Med Assoc 1999;281:1014–18
- LoBue PA, Moser, KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443–7
- American Thoracic Society. Targeted tuberculosis testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221–47
- Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970;17:28–106
- Efficacy of various durations of isoniazid preventative therapy for tuberculosis: five years of follow-up in the IUATL trial: International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982;60:555–64
- Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immuno-deficiency virus. New Engl J Med 1997;337:801–8
- Halsey NA, Coberty JC, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786–92
- Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490–521
- Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatotoxicity: report of an outbreak. Am Rev Respir Dis 1972;106:357–65
- Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatotoxicity: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991–1001
- American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359–74
- Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 1993;159:560–4
- Millard PS, Wiscosky TC, Reade-Christopher SJ, et al. Isoniazid-related fatal hepatitis. West J Med 1996;164:486–91
- Steele MA, Burk RF, DesPrez RM. Toxic hepatotoxicity with isoniazid and rifampin: a meta-analysis. Chest 1991;99:465–71
- Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection. Chest 2005;128:116–23